J 2022

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis

HUSSAIN, Mohammad Salman, A. SINGH, B. ANTONY, Jitka KLUGAROVÁ, M. H. MURAD et. al.

Basic information

Original name

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis

Authors

HUSSAIN, Mohammad Salman (356 India, guarantor, belonging to the institution), A. SINGH, B. ANTONY, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), M. H. MURAD, A. S. JAYRAJ, Alena LANGAUFOVÁ (203 Czech Republic, belonging to the institution) and Miloslav KLUGAR (203 Czech Republic, belonging to the institution)

Edition

Journal of Clinical Medicine, Basel, MDPI, 2022, 2077-0383

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.900

RIV identification code

RIV/00216224:14110/22:00126538

Organization unit

Faculty of Medicine

DOI

UT WoS

000846554700001

Keywords in English

hypertension; preeclampsia; proton pump inhibitors; PPIs; pregnancy; meta-analysis

Tags

Tags

International impact, Reviewed
Změněno: 16/1/2023 13:38, Mgr. Tereza Miškechová

Abstract

V originále

Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23–1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70–1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.

Links

EF18_053/0016952, research and development project
Name: Postdoc2MUNI
LTC20031, research and development project
Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST